SG0 Stock Overview
Operates as a cell therapy, regenerative medicine company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
FibroBiologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.62 |
| 52 Week High | US$12.29 |
| 52 Week Low | US$0.91 |
| Beta | 0 |
| 11 Month Change | -12.08% |
| 3 Month Change | 142.59% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| SG0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -23.8% | -1.0% | -0.5% |
| 1Y | n/a | -16.7% | 8.3% |
Return vs Industry: Insufficient data to determine how SG0 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how SG0 performed against the German Market.
Price Volatility
| SG0 volatility | |
|---|---|
| SG0 Average Weekly Movement | 26.0% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SG0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: SG0's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 10 | Pete O’Heeron | www.fibrobiologics.com |
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
FibroBiologics, Inc. Fundamentals Summary
| SG0 fundamental statistics | |
|---|---|
| Market cap | €84.94m |
| Earnings (TTM) | -€16.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.0x
P/E RatioIs SG0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SG0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.78m |
| Earnings | -US$17.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.2% |
How did SG0 perform over the long term?
See historical performance and comparison